Current treatment status-Undergoing active treatment-Progressive despite several lines of treatment - Page 11 of 24 Posts on Medivizor
Navigation Menu

Current treatment status-Undergoing active treatment-Progressive despite several lines of treatment Posts on Medivizor

Searching patients with relapsed or unresponsive cancer to test a new medication

Posted by on Jul 31, 2019 in Lung cancer | 0 comments

In a nutshell This phase 1b/2 trial will investigate the safety of RMC-4630 and cobimetinib (Cotellic) in relapsed or unresponsive solid tumors.  The main outcomes will be the number of side effects and the overall response rate. This trial is recruiting in a number of US states.  The details Relapsed/refractory (R/R) cancer is a term for...

Read More

Looking for patients with relapsed or unresponsive classical Hodgkin lymphoma to test a new treatment combination

Looking for patients with relapsed or unresponsive classical Hodgkin lymphoma to test a new treatment combination

Posted by on Jul 21, 2019 in Hodgkin's lymphoma | 0 comments

In a nutshell This study is evaluating how well a new chemoimmunotherapy regimen works in treating patients with classical Hodgkin’s lymphoma (cHL) that has come back or stopped responding to treatment. The main outcome to be measured will be the number of patients who have a complete disappearance of all signs of cancer after treatment. This study...

Read More

Quizartinib in the treatment of relapsed or unresponsive acute myeloid leukemia

Quizartinib in the treatment of relapsed or unresponsive acute myeloid leukemia

Posted by on Jul 14, 2019 in Leukemia | 0 comments

In a nutshell This study compared the safety and effectiveness of quizartinib compared to chemotherapy in the treatment of relapsed or unresponsive acute myeloid leukemia (AML). Researchers found that quizartinib was safer and more effective than chemotherapy in these patients. Some background Acute myeloid leukemia (AML) is a cancer of the bone...

Read More

Treatment options for patients with recurrent or non-responsive Hodgkin lymphoma

Treatment options for patients with recurrent or non-responsive Hodgkin lymphoma

Posted by on Jul 9, 2019 in Hodgkin's lymphoma | 0 comments

In a nutshell This article reviewed current treatment options for patients with Hodgkin lymphoma (HL) that has come back (relapsed) or stopped responding to treatment (refractory). Some background Chemotherapy remains the standard first-line treatment for HL. One of the most commonly used regimens is ABVD (doxorubicin, bleomycin, vinblastine,...

Read More

Searching for patients with relapsed or unresponsive non-Hodgkin lymphoma to try a new cell therapy

Posted by on Jun 24, 2019 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This Phase 2 study is evaluating the safety and effectiveness of a new T-cell therapy for B-cell non-Hodgkin’s lymphoma (NHL) that has come back or stopped responding to treatment. The main outcomes to be measured will be the number of patients who experience side effects and overall response after treatment. This trial is recruiting...

Read More

Blinatumomab vs chemotherapy in the treatment of relapsed or unresponsive acute lymphoblastic leukemia

Blinatumomab vs chemotherapy in the treatment of relapsed or unresponsive acute lymphoblastic leukemia

Posted by on Jun 23, 2019 in Leukemia | 0 comments

In a nutshell This study compared the safety and effectiveness of blinatumomab (Blincyto) with chemotherapy in the treatment of acute lymphoblastic leukemia (ALL). Researchers found the survival was higher with blinatumomab than chemotherapy alone. Some background Patients with unresponsive or relapsed ALL treated with chemotherapy have...

Read More

Outcomes of stem cell transplant for patients with acute lymphoblastic leukemia after inotuzumab ozogamicin treatment

Outcomes of stem cell transplant for patients with acute lymphoblastic leukemia after inotuzumab ozogamicin treatment

Posted by on Jun 5, 2019 in Leukemia | 0 comments

In a nutshell This study aimed to investigate the outcomes of allogeneic stem cell transplant (allo-SCT) after treatment with inotuzumab ozogamicin (Besponsa) for patients with relapsed/unresponsive acute lymphoblastic leukemia (ALL). This study concluded that allo-SCT provided optimal long-term survival benefit for these patients. Some...

Read More